spacer gif spacer gif spacer gif spacer gif spacer gif
QUICK SEARCH:   [advanced]


spacer gif
     Home     Help     Feedback     Subscriptions     Archive     Search     Table of Contents    

First published online October 22, 2003
doi: 10.1242/10.1242/jcs.00793

This Article
Right arrow Summary Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JCS
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Odintsova, E.
Right arrow Articles by Berditchevski, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Odintsova, E.
Right arrow Articles by Berditchevski, F.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Tetraspanin CD82 regulates compartmentalisation and ligand-induced dimerization of EGFR

Elena Odintsova, Jens Voortman, Elizabeth Gilbert and Fedor Berditchevski*

Cancer Research UK Institute for Cancer Studies, The University of Birmingham, Edgbaston, Birmingham B15 2TT, UK



View larger version (54K):

[in a new window]
  		Fig. 1. The role of CD82 in the dimerization of ErbB receptors. (A) Expression of ErbB receptors in HB2/ZEO and HB2/CD82 cells. Protein lysates (10 µg) were resolved in 8% SDS-PAGE, transferred to the nitrocellulose membrane and probed with the anti-EGFR (mAb-15), anti-ErbB2 (mAb-1) and anti-ErbB3 (C-17) Abs. (B) Cells were incubated with 125I-EGF (or 125I-TGF{alpha}) at 4°C for 2 hours. The unbound ligand was removed and the cells were treated with 0.5 mM BS3 for 1 hour at 4°C. The complexes were purified as described in the Materials and Methods and resolved in 6% SDS-PAGE. The Abs used were: polyclonal 1005, anti-EGFR; mAb-11, anti-ErbB2; polyclonal C-17, anti-ErbB3. ErbB3 in the immunoprecipitates was probed with the mAb HER-3 Ab-6. (C) 0.5 µg of rs-CD82 was immunoprecipitated using a panel of anti-CD82 mAbs (lanes 2-5) or a negative control (187.1) mAb. 0.2 µg of purified rs-CD82 was used as a positive control (lane 1). The immunoprecipitates were resolved in 10% SDS-PAGE transferred to the membrane and probed with the anti-CD82 mAb (C33). In the additional experiments we found that denatured rs-CD82 is not recognised by any of the anti-CD82 mAbs (results are not shown). (D) The immunoprecipitation analysis was carried out as described in A except that cells were pre-incubated with the recombinant soluble (rs) proteins prior to (1 hour at 4°C) and during binding of 125IEGF. The experiments with HB2/ZEO and HB2/CD82 cells were done in parallel. Both gels were exposed for 14 days.

 


View larger version (57K):

[in a new window]
  		Fig. 2. CD82 does not affect ligand-independent dimerization of EGFR and ErbB2. Cells were pre-treated with 0.5 mM BS3 for 1 hour at 4°C and then subjected to immunoprecipitation analysis as described in Materials and Methods. Immunoprecipitated proteins were resolved in 6% SDS-PAGE, transferred to the nitrocellulose membrane and probed with anti-EGFR (mAb-15) or anti-ErbB2 (mAb-1) Abs.

 


View larger version (26K):

[in a new window]
  		Fig. 3. CD82 does not affect ligand-induced dimerization of ErbB3 with ErbB2. (A) Expression of ErbB receptors in MCF-7/ZEO and MCF-7/CD82 cells. Protein lysates (10 µg) were resolved in 8% SDS-PAGE, transferred to the nitrocellulose membrane and probed with the anti-ErbB2 (mAb-1) and anti-ErbB3 (C-17). (B) MCF-7/ZEO and MCF-7/CD82 cells were incubated with 125I-HRG at 4°C for 2 hours. Formation of ErbB2-ErbB3 dimers was analysed as described in Fig. 1B.

 


View larger version (35K):

[in a new window]
  		Fig. 4. CD82 is associated with ErbB2 and ErbB3. (A) Expression of ErbB proteins in MCF-7/CD82, HB2/CD82 and T47D cells. Equal amounts of total protein lysates were resolved in 8% SDS-PAGE, transferred to the membrane and probed with antibodies to EGFR (mAb Ab-15), ErbB3 (C-17) or ErbB2 (Ab-1). (B) Cells were lysed in 1% Brij98 and the complexes were immunoprecipitated using specific antibodies: anti-ErbB3, mAb-4; anti-ErbB2, mAb-11; anti-CD82, {gamma}C11; negative control, 187.1. The immunoprecipitated complexes were resolved in 8% SDS-PAGE, transferred to a nitrocellulose membrane and probed with Abs to ErbB3 (C-17) or ErbB2 (mAb-1) or CD82 (mAbs C33 and TS82b). (C) Stimulation with HRG does not affect the association of CD82 with ErbB2 and ErbB3. MCF-7/CD82 cells were stimulated with 50 ng/ml HRG for indicated times at 37°C. CD82-ErbB complexes were analysed as described above.

 


View larger version (64K):

[in a new window]
  		Fig. 5. The role of CD82 in compartmentalisation of membrane proteins. Cells were lysed in ice-cold 1% Brij98/MES and the lysates were fractionated in 0.2-0.9 M gradient of sucrose as described in the Materials and Methods. Equal volumes of each fraction were resolved in 10% SDS-PAGE. Distribution of proteins in the gradient fractions was assessed by western blotting using specific antibodies: mAb-15 for EGFR, mAb-1 for ErbB2, mixture of mAbs C33 and TS82b for CD82; mAb 8G6 for EMMPRIN. Caveolin was detected using rabbit polyclonal antibody. The results of a representative (of three) experiment are shown.

 


View larger version (44K):

[in a new window]
  		Fig. 6. CD82 causes redistribution of EGFR and GD1a. HB2/ZEO (A,C,E) and HB2/CD82 cells (B,D,F-J) were grown on glass coverslips for 48 hours. Cells were fixed with paraformaldehyde and indirect immunofluorescence staining was carried out using mAbs to EGFR (A,B), GD1a (C,D), FITC-conjugated cholera toxin (E,F). Double staining was carried out using a combination of anti-GD1a (GD1a-1) and anti-CD82 (C33) mAbs (G,H) or anti-GD1a (GD1a-1) and anti-EGFR (Ab-16) mAbs (I,J). Staining was visualised using FITC-conjugated goat anti-mouse IgG (A-D) or a combination of Texas Red-conjugated goat anti-IgG1 and Alexa Fluor 488-conjugated goat anti-IgG2a (G-J). H and J are digitally magnified highlighted areas of G and I, respectively (x6). Images were acquired using the Nikon Eclipse E600 microscope (Plan Apo 60xA/1.4 oil) and the Leica DC200 digital camera. The images were subsequently processed using the DC200 image processing programme.

 


View larger version (32K):

[in a new window]
  		Fig. 7. CD82 causes redistribution of GD1a in MCF-7 cells. Cells were prepared for immunofluorescence staining as described in the legend to Fig. 6. (A) MCF-7/ZEO cells were stained with anti-GD1a mAb. Staining was visualised using FITC-conjugated goat anti-mouse IgG. (B,C) Double staining of MCF-7/CD82 cells was carried out using a combination of anti-GD1a (GD1a-1) and anti-CD82 ({gamma}C12) mAbs (B and C, respectively). Staining was visualised using a combination of Texas Red-conjugated goat anti-IgG1 and Alexa Fluor 488-conjugated goat anti-IgG2a. (D) Digital superimposition of B and C.

 

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



© The Company of Biologists Ltd 2003